Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Day One Biopharmaceuticals (DAWN) Net Margin: 2024-2025

Historic Net Margin for Day One Biopharmaceuticals (DAWN) over the last 2 years, with Sep 2025 value amounting to -49.48%.

  • Day One Biopharmaceuticals' Net Margin fell 8771.00% to -49.48% in Q3 2025 from the same period last year, while for Sep 2025 it was -113.48%, marking a year-over-year change of. This contributed to the annual value of -156.08% for FY2024, which is N/A change from last year.
  • Latest data reveals that Day One Biopharmaceuticals reported Net Margin of -49.48% as of Q3 2025, which was up 44.63% from -89.37% recorded in Q2 2025.
  • Day One Biopharmaceuticals' Net Margin's 5-year high stood at 38.22% during Q3 2024, with a 5-year trough of -1,372.03% in Q2 2024.
  • Over the past 2 years, Day One Biopharmaceuticals' median Net Margin value was -103.16% (recorded in 2025), while the average stood at -302.44%.
  • The largest annual percentage gain for Day One Biopharmaceuticals' Net Margin in the last 5 years was 128,267bps (2025), contrasted with its biggest fall of 8,771bps (2025).
  • Quarterly analysis of 2 years shows Day One Biopharmaceuticals' Net Margin stood at -225.02% in 2024, then crashed by 8,771bps to -49.48% in 2025.
  • Its last three reported values are -49.48% in Q3 2025, -89.37% for Q2 2025, and -116.94% during Q1 2025.